Nanobiotix (NASDAQ:NBTX – Get Free Report) issued its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08, FiscalAI reports. The business had revenue of $3.17 million during the quarter, compared to analyst estimates of $1.73 million.
Nanobiotix Price Performance
NBTX traded down $1.78 during trading on Thursday, reaching $33.46. The stock had a trading volume of 203,059 shares, compared to its average volume of 88,895. The stock’s 50 day moving average is $38.90 and its two-hundred day moving average is $37.40. Nanobiotix has a one year low of $14.46 and a one year high of $57.14.
Analysts Set New Price Targets
NBTX has been the topic of several research analyst reports. Leerink Partners upped their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Guggenheim started coverage on Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nanobiotix currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.
Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.
Recommended Stories
- Five stocks we like better than Nanobiotix
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
